Efgartigimod Offers Hope in Chronic Inflammatory Demyelinating Polyneuropathy
PHOENIX — A subcutaneous infusion of efgartigimod cut the risk of relapse in patients with a rare but serious immune-mediated neuropathy, according to the phase II ADHERE trial. Patients with diagnosed chronic inflammatory demyelinating polyneuropathy (CIDP) treated with efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) saw a 61% reduction in the risk of relapse versus placebo, […]
Subcutaneous Ocrelizumab Not Inferior to IV Infusion
MILAN — An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III OCARINA II trial showed. During the first 12 weeks of treatment, blood levels of ocrelizumab — measured as the area under the serum concentration time curve (AUC) […]
Injectable Ketamine Shows Promise in Treatment-Resistant Depression
Twice-weekly subcutaneous ketamine helped alleviate symptoms of treatment-resistant depression, according to the phase III KADS study. Among those who received at least one flexible treatment dose (0.5-0.9 mg/kg), ketamine was more than 12-times better at inducing remission of depression than the benzodiazepine midazolam (remission rate 19.6% vs 2.0%, OR 12.1, 95% CI 2.1-69.2, P=0.005), reported […]
Fight Cat Allergies With Newest Asthma Drug?
Subcutaneous immunotherapy treatment (SCIT) for reducing cat allergy symptoms appeared to be more effective and longer lasting with the help of tezepelumab (Tezspire), a monoclonal antibody recently approved for severe asthma, results from a phase I/II trial suggested. While the randomized CATNIP trial failed to meet its primary endpoint — a difference in total nasal […]